The study’s latest data shows that patients on ventilators who received baricitinib plus standard care were 46% less likely to die than those who received placebo plus standard care.
On Tuesday, Eli Lilly and Incyte Corp (INCY.O) announced that their COVID-19 drug baricitinib reduced the risk of death in patients on mechanical ventilation.
The FDA first approved Lilly’s baricitinib combined with Gilead Sciences’ (GILD.O) remdesivir to treat COVID-19 patients.
The FDA last month approved the drug alone or with remdesivir.
- Does This Mean We Stopped Being Animal and Started Being Human Due to ‘Copy Paste’ Errors?
- The One Lifestyle Choice That Could Reduce Your Heart Disease Risk By More Than 22%
- Aging: This Is What Happens Inside Your Body Right After Exercise
- Immune-Boosting Drink that Mimics Fasting to Reduce Fat – Scientists ‘Were Surprised’ By New Findings
- Gun Violence in America: What They Don’t Talk About at the Debate
The study’s latest data shows that patients on ventilators who received baricitinib plus standard care were 46% less likely to die than those who received placebo plus standard care.
Lilly said the study’s findings will be shared with regulatory agencies in the US, EU, and elsewhere.
Source: Reuters
Image Credit: Getty